Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Cidara Therapeutics, Inc. (CDTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/03/2023 8-K Quarterly results
Docs: "Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results"
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
05/11/2023 8-K Quarterly results
Docs: "Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 8-K Quarterly results
Docs: "Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results"
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between Cidara Therapeutics, Inc. and Cantor Fitzgerald & Co. (Common Stock)",
"Underwriting Agreement, by and between Cidara Therapeutics, Inc. and Cantor Fitzgerald & Co. (Series X Convertible Preferred Stock)",
"Opinion of Cooley LLP"
03/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/02/2023 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
03/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/01/2023 8-K Quarterly results
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 6.1% stake in CIDARA THERAPEUTICS, INC.
02/14/2023 8-K Quarterly results
12/16/2022 8-K Quarterly results
11/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/10/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/03/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/31/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
10/21/2022 8-K Quarterly results
09/08/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/02/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/09/2022 8-K Quarterly results
Docs: "Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results"
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/27/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy